An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated SubstitutionsChung‐Feng Huang, Ming‐Lung Yu, Shih‐Jer Hsu et al.|The Journal of Infectious Diseases|2019Cited by 19
HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patientsCheng‐Yuan Peng, Jia‐Horng Kao, Tsung‐Cheng Hsieh et al.|Journal of the Formosan Medical Association|2013Cited by 14
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE studyChen-Hua Liu, Jia‐Horng Kao, Ming‐Lung Yu et al.|Journal of the Formosan Medical Association|2018Cited by 10